Aucta Receives its First Product Approval and Launches

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
76
Aucta Receives its First Product Approval and Launches Vigabatrin for Oral Solution Under the Brand Name Vigadrone™

NEW BRUNSWICK, N.J., July 16, 2018 (GLOBE NEWSWIRE) -- Aucta Pharmaceuticals, Inc. (Aucta) announced today that it has begun shipping Vigabatrin for Oral Solution, USP, 500 mg, following final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application.  Aucta's commercial partner Upsher-Smith Laboratories, LLC (Upsher-Smith) will launch vigabatrin for oral solution under the brand name Vigadrone™, which offers patients and physicians a fully substitutable generic alternative to Sabril ® (vigabatrin) powder for oral solution.*

Vigadrone™ is supported by Upsher-Smith’s Access Pathways ® Program, which is designed to reduce the barriers associated with prescribing vigabatrin by providing brand-quality support to physicians, patients, and caregivers.  To learn more about Access Pathways ® , please visit vigadrone.com or call 1-866-923-1954 Monday-Friday from 8:00 a.m. – 9:00 p.m. (EST).

The Vigabatrin powder market had U.S. sales of approximately $333 million for the 12 months ending December 31, 2017 according to IQVIA.

About Aucta Pharmaceuticals Inc.  Aucta Pharmaceuticals, Inc. (AUCTA, Latin-improved, enhanced ) is a technology based product company focusing on development and commercialization of niche generic and branded specialty products.  The company’s corporate strategy is to focus on proven molecules, use 505(b)(2) regulatory pathway and through innovation, creating new therapeutics with lower scientific risk and meet unmet medical needs in attractive market.  Its specialty division has a therapeutic focus in CNS, Dermatology and Pediatrics.   For more information, visit www.auctapharma.com .

  *Sabril is a registered trademark of Lundbeck.

VIGADRONE and Access Pathways are trademarks of Upsher-Smith Laboratories, LLC.

WHAT IS VIGABATRIN?

Vigabatrin for Oral Solution is a prescription medicine used for the treatment of:

  • Infantile Spasms (IS) in babies 1 month to 2 years of age, if you and your healthcare provider decide the possible benefits of taking vigabatrin are more important than the possible risk of vision loss.
  • Refractory Complex Partial Seizures (CPS) used along with other treatments to treat adults and children 10 years and older if: The CPS does not respond well enough to several other treatments, and You and your healthcare provider decide the possible benefit of taking vigabatrin is more important than the risk of vision loss.

Vigabatrin should not be the first medicine used to treat CPS.

WHAT IMPORTANT SAFETY INFORMATION SHOULD I KNOW ABOUT VIGABATRIN?

WARNING: PERMANENT VISION LOSS See Medication Guide and full Prescribing Information for complete information.

All people who take vigabatrin:

You are at risk for permanent vision loss with any amount of vigabatrin. Your risk of vision loss may be higher the more vigabatrin you take daily and the longer you take it. It is not possible for your healthcare provider to know when vision loss will happen. It could happen soon after starting vigabatrin or any time during treatment. It may even happen after treatment has stopped.

Because vigabatrin might cause permanent vision loss, it is available to healthcare providers and patients only under a special program called the Vigabatrin Risk Evaluation and Mitigation Strategy (REMS) Program. Your healthcare provider will explain the details of this Program to you.

Vigabatrin can damage the vision of anyone who takes it. People who take vigabatrin do not lose all of their vision, but some people can have severe loss, particularly their peripheral vision. With severe vision loss , you may have "tunnel vision". You may also have blurry vision . If this happens, it will not get better.

Tell your healthcare provider right away if you (or your child): might not be seeing as well as before starting vigabatrin; start to trip, bump into things, or are more clumsy than usual; are surprised by people or things coming in front of you that seem to come out of nowhere; or if your baby is acting differently than normal. These changes can mean that vision damage has occurred.

Regular vision testing is recommended. It is recommended that your healthcare provider test your (or your child’s) vision before, during, and after treatment with vigabatrin. Regular vision testing is important because damage can happen before any changes are noticed.

Vision tests cannot prevent the vision damage that can happen with vigabatrin, but they do allow vigabatrin to be stopped if vision has gotten worse. Even these regular vision tests may not show vision damage before it is serious and permanent. Parents, caregivers, and healthcare providers may not recognize the symptoms, or find vision loss in babies, until it is severe.

If you do not have these vision tests, your healthcare provider may stop prescribing vigabatrin for you (or your child). Some people are not able to complete vision testing. If vision testing cannot be done, your healthcare provider may continue prescribing vigabatrin, but will not be able to watch for any vision loss.

Magnetic resonance imaging (MRI) changes in babies with IS. Brain pictures taken by MRI show changes in some babies after they are given vigabatrin. It is not known if these changes are harmful.

Risk of suicidal thoughts or actions. Like other antiepileptic drugs, vigabatrin may cause suicidal thoughts and actions in some people (about 1 in 500 people). Call a healthcare provider right away if you experience these effects, or any symptoms of depression or mood changes.

Do not stop vigabatrin without first talking to a healthcare provider. Stopping vigabatrin suddenly can cause seizures that will not stop.

Vigabatrin can cause serious side effects such as low red blood cell counts (anemia), sleepiness and tiredness, nerve problems, weight gain, and swelling. Because vigabatrin causes sleepiness and tiredness, do not drive, operate machinery, or perform any hazardous task, unless it is decided that these things can be done safely. Vigabatrin may make certain types of seizures worse. Tell your healthcare provider right away if seizures get worse.

Before starting vigabatrin, tell your doctor about all of your (or your child’s) medical conditions , including mental illnesses, and all the medicines you (or your child) take.

If you are breastfeeding or plan to breastfeed, vigabatrin can pass into breast milk and may harm your baby.

If you are pregnant or plan to become pregnant , it is not known if vigabatrin will harm your unborn baby. You and your healthcare provider will have to decide if you should take vigabatrin while you are pregnant.

The most common side effects of vigabatrin in adults include: problems walking or feeling uncoordinated, feeling dizzy, shaking (tremor), joint pain, memory problems and not thinking clearly, and eye problems like blurry vision, double vision, and eye movements that cannot be controlled.

The most common side effects of vigabatrin in children 10 to 16 years of age include weight gain, upper respiratory tract infection, tiredness, and aggression. Also expect side effects like those seen in adults.

The most common side effects of vigabatrin in babies include: sleepiness—some babies may have a harder time suckling and feeding or may be irritable, swelling in the bronchial tubes (bronchitis), ear infection, and irritability.

Tell your healthcare provider if you or your child have any side effect that bothers you or that does not go away.

This is the most important information to know about vigabatrin, but not all of the possible side effects of vigabatrin. For more information, ask your healthcare provider or pharmacist, or please visit vigadrone.com/PI for vigabatrin Medication Guide, full Prescribing Information including Boxed Warning for risk of permanent vision loss, and Instructions for Use.

You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit  www.fda.gov/medwatch , or call 1-800-332-1088.

Patricia Yang (732)640-0030 pr@auctapharma.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ascletis' Preclinical Successes: Future of Obesity Treatment

Updated Category News Views 84

Pharma Giants Eyeing a New Potential Well, it seems the world of pharma is buzzing with Ascletis’ latest developments in the obesity treatment arena. They’ve just showcased some intriguing preclinical data at ObesityWeek® 2026. The standout? A cocktail of advancements that might just put a dent in the obesity epidemic if further studies pan out. ASC30_48: A Daily...

Continue Reading
WirelessCar Rebrands to Reinforce Connected Mobility Vision

Updated Category News Views 41

Evolving Identity for Changing Times Let’s dive right into it—WirelessCar, a name that’s struck chords in the automotive trenches for ages, is taking a bold step by unveiling a new brand identity. Now, don’t roll your eyes just yet. This isn’t another company tapping the rebranding siren for the heck of it. We’re talking about a company that’s been in the...

Continue Reading
Loyalty Programs Cut $1500 Annually for Consumers

Updated Category News Views 56

Loyalty Programs: An Essential Tool for Households In a world where every dollar counts, retail loyalty programs have become more than just a marketing strategy—they're lifelines for American households scraping through each month. According to fresh research by the Retail Industry Leaders Association (RILA) and conducted by market research leader Circana, these...

Continue Reading
FDA Changes Shake Up Medtech Inspections Landscape

Updated Category News Views 75

Inspecting the Changing FDA Landscape If you’ve been treating FDA inspections like a ride down memory lane, it's time for a wake-up call. What F. David Rothkopf plans to tell the medical device teams at the MEDevice Silicon Valley event is simple: the game has changed. The FDA’s Quality Management System Regulation (QMSR) that kicked in on February 2, 2026, isn’t...

Continue Reading
Saint Luis Rey Launches Exclusive Palatinos Vitola

Updated Category News Views 34

New Beginnings for the Saint Luis Rey Brand You think you've seen it all in the cigar world, but then comes a debut like this that lights a fire under the lush tradition of Cuba. Enter Saint Luis Rey's new Palatinos vitola, a blend wrapped in the mystique of exclusivity for La Casa del Habano and Habanos Specialists. Whether you're a seasoned connoisseur or just dipping...

Continue Reading
NestWorks' C500: Shaking Up CNC at Formnext 2026

Updated Category News Views 120

NestWorks C500: A Game Changer for Makers Folks, gather 'round, because NestWorks is turning heads with their C500 desktop CNC machine. As it lands firmly on TIME’s Best Inventions of 2026 list, this ain't just another gadget adorning a workshop—all eyes are on it at Formnext 2026. From November 17–20, Frankfurt is the stage where NestWorks plans to showcase how...

Continue Reading
Home Energy Tips: Embrace the Electrical Panel Shift

Updated Category News Views 13

Why Electrical Panels Matter More Than Ever Back in the day, electrical panels weren't exactly the star of the homeowner show. But times have changed, and those previously mundane boxes of switches and wires now demand a spotlight. Shifts in modern lifestyles have catapulted electrical systems into the spotlight, making upgrades a pressing conversation topic for savvy...

Continue Reading
Midea's R290 Tech: Real Green Cooling Revolution?

Updated Category News Views 215

A Fresh Breeze in Sustainable Cooling In the middle of Kigali’s innovation oasis, Midea RAC stood out at MOP38, the 38th Meeting of the Parties to the Montreal Protocol, flexing its sustainable tech muscles. We're talking about their R290 air conditioning technology—a natural refrigerant with zero ozone footprint and a global warming potential of a mere three. This is...

Continue Reading
Roche Delivers Endotrophin Assay to Nordic Bioscience Lab

Updated Category News Views 52

Roche Opens New Frontier in Diagnostic Biomarkers Get ready to chew on this: Roche Diagnostics is bringing something new to Nordic Bioscience's CLIA lab. They're offering up their Endotrophin research prototype assay on the cobas® e801 Analyzer. Now, what does this mean for the scientific world? Well, it might just shake things up for those battling cardiovascular and...

Continue Reading
Pine Tree Bets Big on Tulsa Hills Shopping Center

Updated Category News Views 85

Pine Tree's Latest Move in Retail Real Estate Ya ever watch a company make a move so aligned with its playbook that it feels like a script straight outta the boardroom? That's Pine Tree with its recent snag of Tulsa Hills Shopping Center for a cool $108 million. This ain't just any retail spot; it's a bustling hub nestled within the posh outskirts of Jenks, Oklahoma....

Continue Reading

Top 5 Most Recently Viewed Articles

Sunrise New Energy Unveils Innovative Solid-State Battery Patent

Updated Category News Views 205

Sunrise New Energy's Patent for Solid-State Battery Innovation Sunrise New Energy Co., Ltd. (NASDAQ: EPOW) has made significant strides in energy technology with the announcement of a groundbreaking invention patent for a novel method of creating lithium cerate-coated graphite iron oxide anode material. This development is a significant leap forward in the realm of...

Continue Reading
Leadership Transition at Lykos Therapeutics Following FDA Setback

Updated Category News Views 103

Leadership Change at Lykos Therapeutics After FDA Setback Amy Emerson has resigned as CEO of Lykos Therapeutics following significant regulatory hurdles. This change comes after the Food and Drug Administration (FDA) recently rejected the company's application for its ecstasy-based therapy aimed at treating post-traumatic stress disorder (PTSD). Consequences of FDA...

Continue Reading
RADCOM to Showcase Innovations at Upcoming Growth Conference

Updated Category News Views 228

RADCOM to Showcase Innovations at Growth Conference RADCOM Ltd. (Nasdaq: RDCM) is gearing up for a prominent appearance at the 28th Annual Needham Growth Conference. The conference will take place at the esteemed Lotte NY Palace Hotel, where the company is excited to highlight its cutting-edge technological advancements. Leadership Team Participation At this significant...

Continue Reading
Shoppers Prioritize Savings Over Convenience, Survey Reveals

Updated Category News Views 81

New Insights into Consumer Preferences During Holidays A recent survey conducted by GoDaddy sheds light on the evolving preferences of consumers as the holiday season approaches. The findings reveal that convenience often takes a backseat to cost savings, which fundamentally impacts how businesses engage with their customers. The Importance of Cost Savings According to...

Continue Reading
Criteo's Insider Trading Insights: What You Need to Know

Updated Category News Views 116

Understanding Recent Insider Trading at Criteo Recently, significant insider trading activity has caught the attention of investors and analysts. Notably, Ryan Damon, Chief Legal Officer at Criteo, made headlines with a prominent stock sale involving his holdings in the company. Insider Sales: A Breakdown During a recent filing, it was disclosed that Ryan Damon sold 3,393...

Continue Reading